<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2200">
  <stage>Registered</stage>
  <submitdate>2/12/2008</submitdate>
  <approvaldate>2/12/2008</approvaldate>
  <nctid>NCT00801255</nctid>
  <trial_identification>
    <studytitle>A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients</studytitle>
    <scientifictitle>A Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability and Antiviral Activity of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591) in Genotype 1 Chronic Hepatitis C Patients. INFORM 1</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PP22205</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - RO5024048
Treatment: drugs - danoprevir
Treatment: drugs - danoprevir
Treatment: drugs - danoprevir
Treatment: drugs - danoprevir
Treatment: drugs - danoprevir

Experimental: Cohort A - 

Experimental: Cohort B - 

Experimental: Cohort C - 

Experimental: Cohort D - 

Experimental: Cohort E - 

Experimental: Cohort F - 

Experimental: Cohort G - 


Treatment: drugs: RO5024048
500mg po bid/100mg po q8h for 7 days

Treatment: drugs: danoprevir
500mg po bid/100mg po q8h for 14 days

Treatment: drugs: danoprevir
1000mg po bid/100mg po q8h for 14 days\n500mg po bid/200mg po q8h for 14 days

Treatment: drugs: danoprevir
1000mg po bid/200mg po q8h for 14 days

Treatment: drugs: danoprevir
1000mg/600mg po twice daily for 14 days

Treatment: drugs: danoprevir
1000mg/900mg po twice daily for 14 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HCV RNA</outcome>
      <timepoint>At each clinic visit, throughout study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Adverse events, laboratory parameters, vital signs</outcome>
      <timepoint>At each clinic visit, throughout study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters;viral resistance</outcome>
      <timepoint>At intervals, throughout study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  adult patients, 18-65 years of age;

          -  chronic hepatitis C, genotype 1.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  decompensated liver disease, or impaired liver function;

          -  presence or history of non-hepatitis C chronic liver disease;

          -  HBsAg or HIV infection;

          -  history of cancer within 5 years, other than localized or in situ cancer of the skin.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>88</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <hospital> - Heidelberg</hospital>
    <hospital> - Melbourne</hospital>
    <postcode>SA 5000 - Adelaide</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3181 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This 7 cohort study will evaluate the efficacy and safety of combination treatment with an
      HCV nucleoside polymerase inhibitor(RO5024048)and an HCV protease
      inhibitor(RO5190591/ITMN-191/danoprevir) in patients with chronic hepatitis C, genotype
      1.Cohorts A,B,C,D and G will be treatment-naive patients, cohort E will be
      treatment-experienced excluding null responders, and cohort F will be null responders.
      Cohorts A and B will evaluate doses of 500mg po bid RO5024048 and 100mg po q8h RO5190591,
      alone or in combination, for up to 7 or 14 days. Cohort C will evaluate combination treatment
      with either 1000mg po bid RO5024048 and 100mg q8h RO5190591 or 500mg po bid RO5024048 and
      200mg q8h RO5190591 for 14 days. Cohort D will evaluate 1000mg po bid RO5024048 and 200mg q8h
      RO5190591 for 14 days.Cohort E will evaluate 1000mg RO5024048/600mg RO5190591 po twice daily
      for 14 days, and Cohorts F and G will evaluate 1000mg RO5024048/900mg RO5190591 po twice
      daily for 14 days. Cohorts will be tested sequentially or in parallel, if supported by
      appropriate safety and pharmacokinetic data.Following the last dose of study medication
      patients have the option of continuing treatment with Standard of care therapies. The
      anticipated time on study treatment is &lt;3 months, and the target sample size is &lt;100
      individuals.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00801255</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>